Suchergebnisse - "Sun, Hui-Chuan"

PubPharm (360)

1

Platelet-to-lymphocyte ratio predicts tumor response and survival of patients with hepatocellular carcinoma undergoing immunotherapies

enthalten in: International immunopharmacology | 2024

von Wang, Z. | Xu, B. | Wang, L. | +8

2

Proteomic and metabolomic features in patients with HCC responding to lenvatinib and anti-PD1 therapy

enthalten in: Cell reports | 2024

von Li, Z. | Wang, J. | Liu, H. | +16

3

Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version)

enthalten in: Journal of clinical and translational hepatology | 2023

von Wang, H. | Chen, J. | Zhang, X. | +45

4

Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma : A Multicenter Study

enthalten in: Liver cancer | 2023

von Xu, B. | Dong, S. | Bai, X. | +25

5

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01) : a multicentre, single-arm, phase 2b study

enthalten in: The Lancet. Oncology | 2023

von Harding, J. | Fan, J. | Oh, D. | +61

6

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma : a multicenter study

enthalten in: BMC cancer | 2023

von Huang, C. | Zhu, X. | Shen, Y. | +22

7

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study

enthalten in: BMC cancer | 2023

von Huang, C. | Zhu, X. | Shen, Y. | +22

8

Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma

enthalten in: Annals of surgical oncology | 2023

von Zhu, X. | Huang, C. | Shen, Y. | +12

9

Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma : A real-world cohort study

enthalten in: Cancer medicine | 2023

von Xu, M. | Huang, C. | Li, M. | +6

10

Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma : a single-center, single-arm, phase 2 study

enthalten in: Signal transduction and targeted therapy | 2023

von Shi, G. | Huang, X. | Wu, D. | +20

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[36]